Emil D. Kakkis
Founder, President, CEO & DirectorDr. Emil D. Kakkis, M.D., Ph.D., is Executive Director of Amlogenyx Inc. Dr. Kakkis has been a Director of Actio Biosciences Inc. and Setara Biosciences, Inc. He is Venture Advisor of Forge Life Science Partners. He is Founder for Ultragenyx Pharmaceutical Inc. He has been the Chief Executive Officer and President of Ultragenyx Pharmaceutical Inc. since April 2010. Dr. Kakkis founded Ultragenyx in April 2010. He served as Scientific Advisor of Tarix Pharmaceuticals LTD. and Edimer Pharmaceuticals Inc. Prior to Ultragenyx, Dr. Kakkis served from September 1998 to February 2009 in various executive capacities at BioMarin Pharmaceutical Inc. He served as an Advisor of BioMarin Pharmaceutical Inc. since March 2009. Dr. Kakkis served as a development consultant to BioMarin from 2009 through 2010. He has specific expert knowledge in genetics and rare diseases and has operational experience in the life sciences sector. He is best known for his work over years to develop novel treatments for rare disorders. He began his work developing an enzyme replacement therapy (Aldurazyme ) for the rare disorder MPS I, with minimal funding and support. He served as Chief Medical Officer of BioMarin Pharmaceutical Inc. from January 2006 to February 2009 and also served as its Senior Vice President. Dr. Kakkis served as Senior Vice President of Business Operations at BioMarin Pharmaceutical Inc. since January 2002 and Senior Vice President of Global Commercial Development. Dr. Kakkis served as a Vice President of BioMarin since September 1998. During his tenure at BioMarin, Dr. Kakkis guided the development and approval of two more treatments for rare disorders, MPS VI and PKU and has contributed to the initiation of other treatment programs for rare disorders, three of which are in clinical development. After 11 years at BioMarin, Dr. Kakkis left industry to initiate an effort to improve the regulatory and clinical development process for rare diseases. He has been Member of Scientific and Technical Advisory Board of imension Therapeutics, Inc. since October 31, 2013. He serves as a Scientific Advisor at Dimension Therapeutics, Inc. He joined BioMarin in 1998 and left in 2009. In early 2009, Dr. Kakkis launched Kakkis EveryLife Foundation in 2009 and funded to accelerate biotech innovation for rare diseases and serves as its President. Dr. Kakkis is a Trustee of Jenny Soriano Living Trust. From 1993 to August 1998, Dr. Kakkis served as an Assistant Professor of Pediatrics at the Harbor-UCLA Medical Center, Division of Genetics, Department of Pediatrics and initiated the enzyme therapy program for MPS I. He has been a Director of Ultragenyx Pharmaceutical Inc. since its inception in April 2010. He is the Author of numerous published articles and abstracts on MPS I and alpha-L-iduronidase. He is a Trustee of Jenny Soriano Living Trust. Dr. Kakkis holds a B.A. in Biology from Pomona College, magna cum laude and received combined MD and PhD degrees from the UCLA School of Medicine’s Medical Scientist Training Program and received the Bogen prize for his research. He is Board certified in both Pediatrics and Medical Genetics. He completed a Pediatrics residency and Medical Genetics Training Fellowship at Harbor- UCLA Medical Center.
Positions
- Company NameUltragenyx Pharmaceutical Inc.Stock CodeRAREPositionFounder, President, CEO & DirectorColleagues
- DGDaniel G. WelchIndependent Non-Executive Chairman
- HHHoward HornExecutive VP of Corporate Strategy & CFO
- KHKarah Herdman ParschauerChief Legal Officer & Executive VP of Corporate Affairs
- EHErik HarrisExecutive VP & Chief Commercial Officer
- ECEric CrombezChief Medical Officer & Executive VP
- MKMatthew K. FustIndependent Director
- MAMichael A. NarachiIndependent Director
- SSShehnaaz SulimanIndependent Director
